Efficacy of Duloxetine and Selective Serotonin Reuptake Inhibitors: Comparisons as Assessed by Remission Rates in Patients With Major Depressive Disorder
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
It has been proposed that serotonin and norepinephrine reuptake inhibitors (SNRIs) may result in higher remission rates of major depressive disorder than therapy with selective serotonin reuptake inhibitors (SSRIs). To test this hypothesis, a meta-analysis of individual patient data (N = 1833) was performed for the complete set of 6 phase II/III studies that compared duloxetine (fixed doses; range, 40-120 mg/d) with 2 SSRIs (paroxetine or fluoxetine; 20 mg/d) in outpatients with major depressive disorder. Remission was defined as an end point score of less than or equal to 7 on the 17-item Hamilton Rating Scale for Depression (HAMD17); alternate outcome criteria were also examined, as were remission rates among the 1044 patients with moderate-to-severe depression (HAMD17 total score greater than or equal to 19). The HAMD17 remission rates were 40.3% (351/871), 38.3% (162/423), and 28.4% (144/507) for duloxetine, the 2 SSRIs, and placebo, respectively. Both active treatments were superior to placebo; the difference between duloxetine and SSRIs was not statistically significant. Similar findings were observed for alternate outcomes. Duloxetine therapy was significantly more effective than therapy with the 2 SSRIs for patients with more severe depression, with remission rates of 35.9% (183/510) versus 28.6% (70/245) (P = 0.046). A secondary analysis of dose-response relationships indicated that this advantage was not attributable to the studies using higher doses of duloxetine. Thus, whereas duloxetine and the 2 SSRIs were comparably efficacious overall, therapy with the serotonin and norepinephrine reuptake inhibitor resulted in a significantly higher remission rate among patients with moderate-to-severe depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Khan, A., Leventhal, R. M., Khan, S. R., & Brown, W. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00007 · Cited by 456
Detke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384
Self-citationDuloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334
Goldstein, D. J., Lu, Y., Detke, M. J., Wiltse, C., Mallinckrodt, C., & Demitrack, M. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132448.65972.d9 · Cited by 314
Self-citation
Cited by
Lutz, W., Stulz, N., & Köck, K. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.019 · Cited by 186
Dunlop, B. W., Binder, E. B., Cubells, J. F., Goodman, M. M., Kelley, M. E., Kinkead, B., Kutner, M., Nemeroff, C. B., Newport, D. J., Owens, M. J., et al. (2012) · Trials · doi:10.1186/1745-6215-13-106 · Cited by 136
“ence in remission rates between medication classes [68].”
Oluboka, O. J., Katzman, M. A., Habert, J., McIntosh, D., MacQueen, G. M., Milev, R. V., McIntyre, R. S., & Blier, P. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx081 · Cited by 104
“Given that about one-half of patients who initiate an antidepressant will fail to achieve remission (Thase et al., 2005; Machado et al., 2006; Thase et al., 2007), several treatment steps may be needed to achieve successful outcomes.”
BackgroundA systematic review of duloxetine and venlafaxine in major depression, including unpublished data
Schueler, Y. ‐., Koesters, M., Wieseler, B., Grouven, U., Kromp, M., Kerekes, M. F., Kreis, J., Kaiser, T., Becker, T., & Weinmann, S. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01599.x · Cited by 87
Saragoussi, D., Touya, M., Haro, J. M., Jönsson, B., Knapp, M., Botrel, B., Florea, I., Loft, H., & Rive, B. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s136343 · Cited by 63
Metadata
- Authors
- Thase, M. E., Pritchett, Y. L., Ossanna, M. J., Swindle, R. W., Xu, J., & Detke, M. J.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2007-12
- Volume
- 27
- Issue
- 6
- Pages
- 672-676
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1994256806
- Cited by
- 113
- References
- 4
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Duloxetine and Selective Serotonin Reuptake Inhibitors: Comparisons as Assessed by Remission Rates in Patients With Major Depressive Disorder. https://app.cochat.ai/papers/10.1097/jcp.0b013e31815a4412
- The paper
- Thase, M. E., Pritchett, Y. L., Ossanna, M. J., Swindle, R. W., Xu, J., & Detke, M. J. (2007). Efficacy of Duloxetine and Selective Serotonin Reuptake Inhibitors: Comparisons as Assessed by Remission Rates in Patients With Major Depressive Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31815a4412
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.